Key Highlights

  • Group Revenue remained broadly stable; Operating Income excluding special items declined 6% at constant currency, a Margin of 11%.
  • Special items were a net negative EUR 161 million; FME25+ delivered EUR 74 million of sustainable savings.
  • Care Delivery revenue increased 1% at constant currency, a margin of 14.7%; Value-Based Care revenue decreased 9%.
  • The 2026 outlook now has operating income growth between flat and a negative mid-single-digit rate at constant currency.

Group Results

Fresenius Medical Care AG (NYSE:FMS), a provider of kidney care products and services, held its third quarter 2026 earnings call, the first with new Chief Executive Officer Shervin Korangy, who joined three weeks earlier. The Chief Financial Officer said group revenue remained broadly stable, supported by organic growth in Care Delivery and partially offset by the anticipated decline in Value-Based Care revenue. Divestitures reduced group revenue growth by 30 basis points.

Operating income excluding special items declined 6% at constant currency, reflecting the anticipated TDAPA reimbursement effect and inflationary pressures, particularly in Care Enablement. The operating income margin was 11%. Special items in the quarter were a net negative EUR 161 million, including one-time costs related to the China strategy refinement, the discontinuation of 4008A production and sales, and the exit of the peritoneal dialysis business.

The FME25+ transformation delivered EUR 74 million of sustainable savings in the quarter, with EUR 54 million of one-time costs, and the company reiterated EUR 250 million of sustainable savings for the full year. Corporate costs increased EUR 28 million year over year, reflecting investments in IT platforms, including the transition to SAP S/4HANA.

Segment Performance

Care Delivery revenue increased 1% at constant currency and 2% organically. In the United States, organic revenue growth was 1% and same market treatment growth declined 1.1%, while international same market treatment growth was 1.4%. Care Delivery operating income increased 2% at constant currency, with a margin of 14.7%, and underlying operating income excluding TDAPA effects increased 21%.

Value-Based Care revenue decreased 9% organically and at constant currency, reflecting a change in the risk contracting structure of one larger contract. Operating income excluding special items was EUR 1 million versus a loss of EUR 21 million in the prior year.

Care Enablement revenue grew 5% organically and at constant currency, supported by the 5008X CAREsystem rollout in the United States and pricing, and its earnings increased 4%. The company now assumes group Inflation headwinds above the top end of the EUR 300 million range originally assumed.

Cash Flow, Buyback and Outlook

Operating Cash Flow increased 8% in the quarter, and net Debt and Lease liabilities increased 6% year over year. Under the second EUR 1 billion share buyback program, 9.1 million shares, or 3.4%, had been repurchased as of September 30 for EUR 357 million. The net Leverage Ratio was 2.6x, against a target corridor of 2.5x to 3x.

For 2026, management continues to project broadly flat revenue at constant currency and now projects operating income growth between flat and a negative mid-single-digit rate, in the lower half of prior guidance. A fuller outlook for 2027 is to be provided with full-year results in February.

Items to Follow

Investors can follow the 5008X rollout, with 348 clinics, or 14% of clinics, converted by the end of September and a target of converting 20% of the install base by year-end, along with the U.S. rollout of HV-HDF.

Management also noted that TDAPA headwinds increase in the fourth quarter as the TDAPA period for phosphate binders ends, and that the company is implementing corrective and preventive actions following FDA audits at its facilities.